TABLE 1:

Characteristics of Five Patients with Identified GI Polyps

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Sex / Cancer Diagnosis / Age of Diagnosis	Female / AML / 10 months	Male / ALL / 2 years 11 months	Female / ALL / 9 years 8 months	Male / ALL / 1 year 9 months	Male / ALL / 15 years 11 months
Initial Cancer Therapy	CCG regimen C 2891: IT Ara-C, 6-thioguanine, Decadron Ara-C, daunomycin etoposide	POG Protocol 9605: prednisone, vincristine, L-asparaginase, IT methotrexate, Ara-C, and hydrocortisone and continuation therapy with 6-MP, methotrexate, vincristine, prednisone, and IT methotrexate	POG Protocol 9605: prednisone, vincristine, L-asparaginase, IT methotrexate, Ara-C, and hydrocortisone and continuation therapy with 6-MP, methotrexate, vincristine, prednisone, and IT methotrexate.	CCG regimen 1991: TBI, thiotepa, cyclophosphamide, methotrexate, and tacrolimus	COG AALL1131: Ara-C, vincristine, prednisone daunorubicin peg-asparaginase, IT methotrexate
Re-Induction	Twice weekly Ara-C and idarubicin	Vincristine, prednisone, L-asparaginase and daunomycin	Prednisone, doxorubicin, L-asparaginase, vincristine, dexamethasone, intrathecal Ara-C, methotrexate	Methotrexate, Ara-C, etoposide, cyclophosphamide, vincristine, mercaptopurine, dexamethasone, doxorubicin, and pegaspargase	N/A
HCT Conditioning	Cyclophosphamide, Ara-C, ATG, TBI 1200 cGy with 900 cGy cranial radiation	Ara-C, cyclophosphamide, TBI 1400 cGy	Ara-C, cyclophosphamide, TBI 1400 cGy, with 900 cGy cranial boost	Thiotepa, cyclophosphamide, TBI 1200 cGy	Thiotepa, cyclophosphamide, TBI 1200 cGy with testicular boost
Donor Source and HLA Matching	Mother - 5/10 HLA Matched CD34-selected peripheral blood stem cell infusion	Unrelated Donor – 8/8 HLA Matched partially T-cell depleted bone marrow transplant	Unrelated Donor – 7/8 HLA Matched partially T-cell depleted bone marrow transplant	Sister – 8/8 HLA Matched CD34-selected peripheral blood stem cell infusion	Unrelated Donor – 10/10 HLA Matched partially T-cell depleted bone marrow transplant
Post-Transplant Immune Suppression	None	Cyclosporine	Cyclosporine	Tacrolimus	Tacrolimus, sirolimus
Max Acute GVHD	None	Skin stage 2, GI stage 4 (Grade III overall)	Skin stage 1, GI stage 4 (Grade III overall)	GI stage 1 (Grade II overall)	Skin grade 1, GI stage 4 (Grade III overall)
Chronic GVHD	None	Chronic Skin GVHD	Chronic Skin GVHD	None	Chronic Skin & GI GVHD
Time from HCT to 1st Polyp Identification	4.5 years	4.5 years	5.75 years	3.25 years	0.75 years
Family History	Father had stomach ulcers	Maternal grandfather had 29 colonic polyps	None	None	None

CCG – Children’s Cancer Study Group; COG – Children’s Oncology Group; GI – gastrointestinal; GVHD – graft-versus-host disease; HCT – hematopoietic cell transplantation; HLA – human leukocyte antigen; IT – intrathecal; POG – Pediatric Oncology Group